ITMCTR2100004974招募中4 期
A randomized, controlled, open, multi-center clinical study on the effectiveness and safety of Kangai injection in the treatment of cancer-induced fatigue
Jiangsu Provincial Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 80（—）
- 性别
- All
入选标准
- •1. Determined by histopathology or cytology as a tumor patient (lung cancer, rectal cancer, malignant lymphoma, gynecological malignant tumor);
- •2. Patients receiving chemotherapy;
- •3. ECOG score 0-1 points;
- •4. Meet the diagnostic criteria for cancer-related fatigue, and have a fatigue score >=4 (using a 0-10 numerical scale to score the degree of fatigue, 0 = no fatigue, 10 = the most severe fatigue);
- •5. Age from 18 to 80 years old;
- •6. Voluntarily sign written informed consent.
排除标准
- •1. People with severe mental disorders;
- •2. People with speech and cognitive impairment;
- •3. People with allergies or known to be allergic to the drugs and their ingredients used in this test;
- •4. Patients with abnormal liver and kidney function indexes (ALT, AST, Scr exceed the upper limit of the normal reference range by 1.5 times);
- •5. Pregnant and lactating women, or women of childbearing age whose blood and/or urine HCG test results are positive before the test;
- •6. Patients with poor compliance;
- •7. Other patients who the investigator thinks are not suitable for enrollment.
研究者
相似试验
招募中
1 期
A prospective, randomized,open, multi-center clinical trial evaluating the efficiency and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)novel coronavirus pneumonia (COVID-19)ITMCTR2000002972Beijing hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-NLovartis Pharma Services AG300
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine (LDT600) 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-DEovartis Pharma Services AG300
进行中（未招募）
不适用
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BTreatment of naïve patients with HBeAg-positive compensated chronic hepatitis BMedDRA version: 8.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2006-004003-18-BEovartis Pharma Services AG300
进行中（未招募）
1 期
A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and with telbivudine monotherapy in treatment naïve patients with HBeAg-positive chronic hepatitis BEUCTR2006-004003-18-GBovartis Pharma Services AG